Patents Examined by Hemant Khanna
-
Patent number: 7297681Abstract: The invention relates to compounds of formula I which are useful for elevating the plasma level of growth hormone in a mammal as well as for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders associated with growth hormone secretion deficiency.Type: GrantFiled: May 4, 2004Date of Patent: November 20, 2007Assignee: Æterna Zentaris GmbHInventors: Jean Martinez, Jean-Alain Fehrentz, Vincent Guerlavais
-
Patent number: 7288525Abstract: The present invention provides a method for reducing the amount of homocysteine in the blood of an individual. The method comprises administering to the individual a composition comprising a homocysteine lowering agent in an amount effective to lower the amount of homocysteine in the blood of the individual. The homocysteine lowering agent is selected from A dipeptides consisting of isoleucine, leucine, valine, or glycine and combinations thereof; tripeptides consisting of isoleucine, leucine, valine, or glycine and combinations thereof; alpha-ketobutyrate; propionyl A CoA, and combinations thereof.Type: GrantFiled: December 28, 2005Date of Patent: October 30, 2007Assignee: The Research Foundation of State University of New YorkInventor: Thomas Guttuso, Jr.
-
Patent number: 7262169Abstract: The present invention is directed to the improved synthesis of compounds of formula (I) an intermediate compound which is useful in the synthesis of the anticancer agents known as PSA conjugates.Type: GrantFiled: October 18, 2000Date of Patent: August 28, 2007Assignees: Merck & Co., Inc., Merck Sharp & Dohme LimitedInventors: Michael Stewart Ashwood, Brian Christopher Bishop, Ian Frank Cottrell, Khateeta Moneek Emerson, David Hands, Guo Jie Ho, Joseph Edward Lynch, Yao Jun Shi, Robert Darrin Wilson
-
Patent number: 7256200Abstract: Composition and methods of treating pain and reducing, reversing, or preventing tolerance to opiate analgesics are disclosed. The composition and method utilize an opiate analgesic and a calcium calmodulin kinase (CaMKII) inhibitor as active agents to treat pain in mammals, including humans.Type: GrantFiled: January 30, 2004Date of Patent: August 14, 2007Assignee: The Board of Trustees of the University of Illinois, a body corporate and politic of the State of IllinoisInventor: Zaijie Wang
-
Patent number: 7238791Abstract: Analogs of 6-monoacetyl morphine (6-MAM) are described. These include analogs derivatized at either the C-3 position, the C-6 position, or the nor position of the molecule. These analogs allow for elaboration with linkers terminated by a functional group such as an activated ester, the functional groups being useful for attaching the molecule to other entities such as proteins, polysaccharides, and reporter groups.Type: GrantFiled: December 16, 2005Date of Patent: July 3, 2007Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Gerald F. Sigler
-
Patent number: 7238664Abstract: The invention relates to the combined administration of a pulmonary surfactant and a PDE5 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental.Type: GrantFiled: June 15, 2004Date of Patent: July 3, 2007Assignee: Altana Pharma AGInventor: Stefan-Lutz Wollin
-
Patent number: 7232879Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.Type: GrantFiled: January 30, 2004Date of Patent: June 19, 2007Assignee: Eli Lilly and CompanyInventors: John A. Galloway, James A. Hoffmann
-
Patent number: 7217688Abstract: The invention provides isolated agents having novel chemical structures and possessing superior activity as derepressors of IAP inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase. The invention further provides assay methods employing labeled compounds of the invention, especially fluorescent labeled compounds.Type: GrantFiled: July 19, 2005Date of Patent: May 15, 2007Assignees: The Burnham Institute, Torrey Pines Institute for Molecular StudiesInventors: John C. Reed, Richard A. Houghten, Adel Nefzi, John M. Ostresh, Clemencia Pinilla, Kate Welsh
-
Patent number: 7214664Abstract: Dipeptide, and tripeptide and tetrapeptide ester derivatives of bioactive agents are provided wherein the parent agents are substrates effluxed by the P-gp transporter. The derivatives are useful in treating the same condition as the bioactive agent. Also disclosed is a method for preparing a bioactive agent for targeted delivery by nutrient or peptide transporters comprising linking the agent to one or more groups of the formula —X—Y(n)-Z(n?)-Z?(n?)-R; wherein each X, Y, Z, and Z? is independently Met, Val, Thr, Tyr, Trp, Ser, Ala or Gly; R is independently H or an amino-protecting group; n=1, and each, n?, or n? is independently 0 or 1.Type: GrantFiled: November 22, 2005Date of Patent: May 8, 2007Assignee: The Curators of the University of MissouriInventors: Ashim K. Mitra, Soumyajit Majumdar, Ritesh Jain, Yasser Nashed
-
Patent number: 7202218Abstract: The present invention provides an antagonist peptide of interleukin-6 (IL-6), wherein the peptide comprises a amino acid sequence which is selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7. The peptide of the invention is able to specifically bind IL-6R and compete for the binding of IL-6 to IL-6R, to block IL-6-induced signal transduction and therefore effectively inhibits IL-6-mediated antiapotopsis and angiogenesis, and further inhibits IL-6-mediated tumor growth.Type: GrantFiled: August 3, 2005Date of Patent: April 10, 2007Assignee: National Taiwan UniversityInventors: Lin-Hung Wei, Jen-Liang Su, Min-Liang Kuo
-
Patent number: 7169890Abstract: The invention regards a process for the production of ramoplanin-like derivatives of formula (I): RAMO-NC—CO—R (I), wherein the radical R represents a hydrocarbon radical and the portion RAMO-NH— represents deacylated ramoplanin, any of its factors or ramoplanose. The compound of Formula (I) are obtained by reacting a carboxylic acid R—COOH with deacylated ramoplanin, any of its factors or ramoplanose protected on the ornitine amino groups. New compounds wherein the hydrocarbon radical R is different form those characaterizing the ramoplanin and ramoplanose natural products and their tetrahydro-derivatives are calimed. The new compounds have the same or better antinfective activity, lower haemolytic effect and better tolerability profile than ramoplanin.Type: GrantFiled: February 26, 2003Date of Patent: January 30, 2007Assignee: Vicuron Pharmaceuticals Inc.Inventors: Romeo Ciabatti, Sonia Maffioli, Anna Checchia, Gabriella Romano, Gianpaolo Candiani, Gianbattista Panzone